Please login to the form below
RA
This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.
Gilead and EVOQ Therapeutics partner in deal potentially worth over $650m
Gilead and EVOQ Therapeutics (EVOQ) have entered into a collaboration and licensing agreement aimed at advancing immunotherapies for the treatment of rheumatoid arthritis (RA) and lupus. ... We look forward to working with the Gilead team to advance new
Latest news
-
Roche’s COVID-19 antibody receives FDA approval for hospitalised adults
Like Actemra, which was approved in 2010 to treat rheumatoid arthritis, Kineret has been on the US market for more than two decades for the treatment of RA, and has been
-
AbbVie receives extended SMC recommendation for Rinvoq in rheumatoid arthritis patients
The treatment was previously reimbursed by the SMC for those with severe RA. ... Typically, most patients develop RA between the age of 40 and 60, but the condition can affect people of any age.
-
Astellas to support development of Taysha’s AAV-based gene therapy programmes
Also commenting on the deal, RA Session II, Taysha’s chief executive officer, said: “We are excited to enter this strategic investment with Astellas, a premier biopharmaceutical company with global
-
NICE recommends Grifols’ Tavlesse for chronic immune thrombocytopenia
With NICE’s recommendation, which is specifically for patients who have previously had a TPO-RA, or who are unable to receive a TPO-RA, Tavlesse can now be accessed and
-
NHS Scotland to offer Jyseleca for patients with moderate rheumatoid arthritis
More than 40, 000 people in Scotland live with RA and an estimated 35% of those will have moderate disease activity. ... With RA, the sooner a patient’s treatment starts, the better chance there is of delaying disease progression.
More from news
Approximately 9 fully matching, plus 162 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
Similar retrospective positive findings were recently published for the anti-diabetic, glucagon-like peptide-1 receptor agonist (GLP1-RA), which was also found to reduce neuroinflammation.
-
Setting up for success in a post-Brexit, post-pandemic Britain
and Rheumatoid Arthritis (RA). ... More than 400, 000 people in the UK live with RA (around 380, 000 in England), and it is recognised as a condition that can cause debilitating physical pain, affect mental
-
Drug launches to watch in 2019
The good news for the company is that it has not one but two potential blockbusters likely to gain approval in 2019: Upadacitinib (AbbVie) for RA and risankizumab (co-marketed with ... Likewise, upadacitinib will face competition in both RA and atopic
-
Deal Watch January 2018
Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).
-
European CTR implementation advances ethical assessment of clinical trials
Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC
More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest from PMHub
-
Food Allergy – Is avoidance the only option?
Accessed May 11, 2022. Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA.
-
Understanding behaviour change: A Porterhouse Insights specialism
Annu Rev Psychol 2015; 66: 799–823. 5. Ferrer RA and Mendes WB.
-
RA Consultants Private Limited
RA Consultants Private Limited.
-
The other side of … rheumatoid arthritis
So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed.
-
Lucid Group reaches the finals of the PM360 2020 Trailblazer Initiative Awards
LiBRA is a multichannel program, focused on inspiring and enabling clinical behavior change to achieve better disease control for patients with RA. ... Lisa Druce, Managing Director, Lighthouse Medical Communications US, commented “RA is a chronic
More from PMHub
Approximately 2 fully matching, plus 29 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- LEO Pharma enters clinical trial partnership with ICON
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
- The Considered appoints Bam Zahraie as chief experience officer
- The impact of pharma congresses on HCPs – virtual and in person
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- A relentless commitment to neuroscience
- Putting the ovation into innovation: trends from ESMO
- Sanofi to acquire Provention Bio in deal worth $2.9bn
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
